Efforia, Inc.

Efforia, Inc. is a United States company based in New York that operates a digital platform for consumer-led, clinical-quality experimentation. Its core proposition is captured in the phrase 'Determine What Works for You With Real Life Trials': rather than relying on contradictory or unverified advice, users design or join structured protocols, try a product or service under guided conditions, track outcomes with quick check-ins, and receive a personal results report so they can keep what works and drop what does not. The platform is organized around several connected features. Users can 'Choose your path' by creating a protocol for something they want to test or joining one that already exists. 'Try Products You've Always been Curious About' lets a participant follow a guided plan with a defined duration and total price, such as a 90-day trial of Neuralli Mood at $222.75, a 90-day evaluation of Heart & Soil's Lifeblood on iron and energy levels at $384.00, a 70-day MyVitalC trial for sleep and everyday headache management at $218.00, a 30-day evaluation of SleepWhale Drops for rest and resilience at $121.00, a 30-day WAVwatch study on sound and stress at $597.00, and a 42-day 'Porn Abstinence Challenge' at $269.00. Each trial is associated with a named 'Protocol Coach' — individuals such as Matthew Amsden, Dillon Randolph, Chris Burres, and John Bamber appear in the examples shown on the platform. A second pillar is the 'Effort Tracker', which helps users see what pays off and what does not, so they can keep what is working, drop what is not, and know what to try next. A third is expert engagement: participants can follow expert-built protocols and observe what actually changes for them over time. The company frames the experience as 'Real-life rigor. Personal answers. In minutes a day.' Efforia positions itself as 'Democratizing Clinical Trials'. Its stated mission is to empower anyone to craft protocols, test hypotheses, and participate in experiments yielding scientifically valid evidence on 'what works' across a spectrum of topics encompassing the human experience. The company argues that consumers have goals but are left to decipher what truly works amid a sea of contradictory and unverified advice, which ultimately hurts providers and brands. It also argues that the randomized controlled trial (RCT), while hailed as the gold standard, has drawbacks — narrow focus, prohibitive cost, and long timelines — that hinder its use for consumers' personal decision-making, and that the evidence needed for life's crucial decisions about health, happiness, and productivity typically does not exist. Efforia's answer is digital technology applied to evidence generation: it says digital technology has democratized travel, finance, and journalism, and now Efforia empowers anyone to generate evidence about what truly betters the human condition. The platform emphasizes validated results through personal clinical-quality experiments and outcomes that can be tested and retested, step-by-step guidance with expert coaching, protocol design and execution with AI assistance for crafting treatment plans, refining research questions, and establishing precise measures, and a changed evidence-generation business model that lets participants earn revenue while creating evidence. The company also invites brands and providers to 'Generate Proof Your Customers Can See', suggesting a two-sided model serving both individual consumers and commercial partners.

Efforia, Inc. is a United States company based in New York. Public evidence about the company is concentrated in its own platform and about pages, which describe its purpose and product model rather than a long corporate chronology; no founding date, founder names, funding events, or ownership details are established in the available sources. The company's stated rationale is that consumers have goals but are left to decipher what truly works amid a sea of contradictory and unverified advice, and that this ultimately hurts both providers and brands. Efforia also argues that the randomized controlled trial (RCT), while hailed as the gold standard, has drawbacks — narrow focus, prohibitive cost, and long timelines — that hinder its use for consumers' personal decision-making. In its framing, people make life's crucial decisions about health, happiness, and productivity without concrete evidence because such evidence typically does not exist. Efforia's response has been to build a digital platform for evidence generation. It draws an analogy to digital technology having democratized travel, finance, and journalism, and positions itself as doing the same for evidence about what truly betters the human condition. The platform's stated capabilities include letting anyone build evidence, producing validated results through personal clinical-quality experiments and outcomes that can be tested and retested, providing step-by-step guidance with expert coaching, supporting protocol design and execution with AI assistance for crafting treatment plans, refining research questions, and establishing precise measures, and changing the evidence-generation business model so that participants can earn revenue while creating evidence. In its consumer-facing form, the platform presents 'Real Life Trials'. Users choose a path — creating a protocol for what they want to test or joining an existing one — then try a product or service with a guided plan and quick check-ins, and receive a personal results report so they can keep what works and drop what does not. The homepage shows a catalog of such trials with named Protocol Coaches, defined durations, and total prices: a 90-day trial of Neuralli Mood at $222.75 (Matthew Amsden), a 90-day evaluation of Heart & Soil's Lifeblood on iron and energy levels at $384.00 (Dillon Randolph), a 70-day MyVitalC trial for sleep and everyday headache management at $218.00 (Chris Burres), a 30-day evaluation of SleepWhale Drops for rest and resilience at $121.00 (Matthew Amsden), a 30-day WAVwatch study on sound and stress at $597.00 (John Bamber), and a 42-day 'Porn Abstinence Challenge' at $269.00 (Matthew Amsden). Alongside the trials, the platform offers an 'Effort Tracker' to see what pays off and what does not, and an expert engagement layer where users follow expert-built protocols and observe what actually changes for them over time. The company summarizes the experience as 'Real-life rigor. Personal answers. In minutes a day.' It also addresses brands and providers directly with the promise to 'Generate Proof Your Customers Can See', indicating that the platform is intended to serve commercial partners seeking credible consumer evidence as well as individual participants.

Democratizing clinical trials: a digital platform that lets anyone craft protocols, test hypotheses, and generate scientifically valid evidence about 'what works', combining real-life rigor with personal answers in minutes a day.

• Real Life Trials

  Guided consumer trials of products and services with defined durations, prices, and Protocol Coaches, ending in a personal results report.

• Effort Tracker

  Tracking feature to see what pays off and what does not, so users can keep what works, drop what does not, and know what to try next.

• Expert Test Protocols

  Expert-built protocols that participants can follow while observing what actually changes for them over time.

• AI-assisted protocol design

  Help with crafting treatment plans, refining research questions, and establishing precise measures.

• Brands & Providers evidence generation

  Offering to generate proof that customers can see, with a business model that lets participants earn revenue while creating evidence.

1. 1Determine What Works for You With Real Life Trialsapp.efforia.com
2. 2Democratizing Clinical Trials on Efforiaapp.efforia.com
3. 3Efforia, Inc. (United States) — Wikidatawikidata.org
4. 4Efforia official websiteefforia.com